Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma

Journal of Surgical Research

Volumn 84, Issue 1, 1999, Pages 88-93

  Ahrendt, Steven A ^a   Eisenberger, Claus F ^b   Yip, Lin ^b   Rashid, Asif ^b   Chow, John T ^b   Pitt, Henry A ^a   Sidransky, David ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biliary tract tumors; Cholangiocarcinoma; Chromosome 9p21; P16; Primary sclerosing cholangitis

Indexed keywords

MICROSATELLITE DNA; PROTEIN P16;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA DETERMINATION; DNA METHYLATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0033150246     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5615     Document Type: Article

References (38)

1. Ahrendt, S. A. Pitt, H. A. Nakeeb, A. Klein, A. S. Lillemoe, K. D. Kalloo, A. N. Cameron, J. L. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis, J. Gastrointest. Surg.
2. Rosen C. B., Nagorney D. M., Wiesner R. H., Coffey R. J. Jr., LaRusso N. F. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann. Surg. 213:1991;21.
3. Farges O., Malassagne B., Sebaugh M., Bismuth H. Primary sclerosing cholangitis: Liver transplantation or biliary surgery. Surgery. 117:1995;146.
4. Bergquist A., Glaumann H., Persson B., Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology. 27:1998;311.
5. Broome U., Olsson R., Loof L., Bodemar G., Hultcrantz R., Danielsson A., Prytz H., Sandberg-Gertzen H., Wallerstedt S., Lindberg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 38:1996;610.
6. Kornfeld D., Ekbom A., Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 32:1997;1042.
7. Goss J. A., Shackleton C. R., Farmer D. G., Arnaout W. S., Seu P., Markowit J. S., Martin P., Stribling R. J., Goldstein L. I., Busuttil R. W. Orthotopic liver transplantation for primary sclerosing cholangitis: A 12-year single center experience. Ann. Surg. 225:1997;472.
8. Abu-Elmagd K. M., Malinchoc M., Dickson E. R., Fung J. J., Murtaugh P. A., Langworthy A. L., Demetris A. J., Krom R. A. F., Van Thiel D. H., Starzl T. E. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg. Gynecol. Obstet. 177:1993;335.
9. Wiesner R. H., Porayko M. K., Hay J. E., LaRusso N. F., Steers J. L., Krom R. A., Dickson E. R. Liver transplantation for primary sclerosing cholangitis: Impact of risk factors on outcome. Liver Transplant Surg. 2:1996;99.
10. Ramage J. K., Donaghy A., Farrant J. M., Iorns R., Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 108:1995;865.
11. Nichols J. C., Gores G. J., LaRusso N. F., Wiesner R. H., Nagorney D. M., Ritts R. E. Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin. Proc. 68:1993;874.
12. Campbell W. L., Ferris J. V., Holbert B. L., Thaete F. L., Baron R. L. Biliary tract carcinoma complicating primary sclerosing cholangitis: Evaluation with CT, cholangiography, US, and MR imaging. Radiology. 207:1998;41.
13. Keiding S., Hansen S. B., Rasmussen H. H., Gee A., Kruse A., Roelsgaard K., Tage-Jensen U., Dahlerup J. F. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 28:1998;700.
14. Caldas C., Hahn S. A., Hruban R. H., Redston M. S., Yeo C. J., Kern S. E. Detection of K-ras mutation in stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54:1994;3568.
15. Tada M., Omata M., Kawai S., Saisho H., Ohto M., Saikki R. K., Sninsky J. J. Detection ofras. Cancer Res. 53:1993;2472.
16. Iguchi H., Sugano K., Fukayama N., Ohkura H., Sadamoto K., Ohkoshi K., Seo Y., Tomoda T., Funakoshi A., Wakasugi H. Analysis of the Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology. 110:1996;221.
17. Van Laethem J. L., Vertongen P., Deviere J., van Rampelbergh J., Rickaert F., Cremer M., Robberecht P. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut. 36:1995;781.
18. Ahrendt S. A., Rashid A., Chow J. T., Pitt H. A., Eisenberger K. F., Sidransky D. Effect of p53 overexpression and K-ras gene mutations on survival in patients with primary sclerosing cholangitis associated cholangiocarcinoma. Gastroenterology. 114:1998;A555.
19. Schutte M., Hruban R. H., Geradts J., Maynard R., Hilgers W., Rabindran S. K., Moskaluk C. A., Hahn S. A., Schwarte-Waldhof I., Schmiegel W., Baylin S. B., Kern S. E., Herman J. G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:1997;3126.
20. Yoshida S., Todoroki T., Ichikawa Y., Hanai S., Suzuki H., Hori M., Fukao K., Miwa M., Uchida K. Mutations of the p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 55:1995;2756.
21. Wilentz R. E., Geradts J., Maynard R., Offerhaus G. J. A., Kang M., Goggins M., Yeo C. J., Kern S. E., Hruban R. H. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res. 58:1998;4740.
22. Dickson E. R., Murtaugh P. A., Wiesner R. H., Grambsch P. M., Fleming T. R., Ludwig J., LaRusso N. F. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology. 103:1993;1893.
23. Goelz S. E., Hamilton S. R., Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem. Biophys. Res. Commun. 130:1985;118.
24. Reed A. L., Califano J., Cairns P., Westra W. H., Jones R. M., Ahrendt S., Koch W., Eby Y., Sewell D., Nawroz H., Bartek J., Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56:1996;3630.
25. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93:1996;9821.
26. Nakeeb A., Pitt H. A., Sohn T. A., Coleman J., Abrams R. A., Piantadosi S., Hruban R. H., Lillemoe K. D., Yeo C. J., Cameron J. L. Cholangiocarcinoma: A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224:1996;463.
27. Liggett W. H. Jr., Sidransky D. Role of the p16 tumor-suppressor gene in cancer. J. Clin. Oncol. 16:1998;1197.
28. Ahrendt S. A., Pitt H. A., Kalloo A. N., Venbrux A., Klein A. S., Herlong J. F., Coleman J., Lillemoe K. D., Cameron J. L. Primary sclerosing cholangitis: Resect, dilate, or transplant. Ann. Surg. 227:1998;412.
29. Hahn S. A., Bartsch D., Schroers A., Galehdari H., Becker M., Ramaswamy A., Schwarte-Waldhoff I., Maschek H., Schmiegel W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 58:1998;1124.
30. Diamantis I., Karamitopoulou E., Perentes E., Zimmerman A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology. 22:1995;774.
31. Ohashi K., Tstsumi M., Nakajima Y., Nakano H., Konishi Y. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br. J. Cancer. 74:1996;930.
32. Tomono H., Nimura Y., Aono K., Nakashima I., Iwamoto T., Nakashima N. Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilatation. Am. J. Gastroenterol. 91:1996;1211.
33. Matsubara T., Sakurai Y., Sasayama Y., Hori H., Ochiai M., Funabiki T., Matsumoto K., Hirono I. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreatobiliary maljunction. Cancer. 77:1996;1752.
34. Hruban R. H., Sturm P. D., Slebos R. J., Wilentz R. E., Musler A. R., Yeo C. J., Sohn T. A., van Velthuysen M. L., Offerhaus G. J. Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases to the liver? A molecular analysis of 101 liver lesions from 93 patients. Am. J. Pathol. 151:1997;943.
35. Cairns P., Polasckik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., Rutter J., Buckler A., Gabrielson E., Tockman M., Cho K. R., Hedrick L., Bova G. S., William I., Koch W., Schwab D., Sidransky D. Frequency of homozygous deletion at p16/ckdn2 in primary human tumors. Nature Genet. 11:1995;210.
36. Van der Wiet P., Nawroz H., Hruban R. H., Corio R., Tokino K., Koch W., Sidransky D. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 54:1994;1156.
37. Wistuba I., Lam S., Behrens C., Virmani A. K., Fong K. M., LeRiche J., Samet J. M., Srivastava S., Minna J. D., Gazdar A. F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1997;1366.
38. Seymour A., Hruban R. H., Redston M. S., Caldas C., Powell S. M., Kinzler K. W., Yeo C. J., Kern S. E. Allelotype of pancreatic adenocarcinoma. Cancer Res. 54:1994;2761.